Last updated: February 15, 2026
Product Overview
NDC 51672-5294 refers to Tecentriq (atezolizumab), a monoclonal antibody targeting PD-L1, approved for various cancers, including bladder, non-small cell lung, triple-negative breast, and other solid tumors. It is marketed by Roche. The drug entered the market in 2016 and has gained regulatory approvals in multiple regions.
Market Size and Growth Drivers
-
Global Oncology Immunotherapy Market: Valued at approximately $39 billion in 2022, expected to grow at a CAGR of 12-14%, driven by expanding indications and increased cancer prevalence (Fortune Business Insights[1]).
-
Indications and Exclusivity: Tecentriq’s approved uses cover numerous cancers with high unmet needs, fostering a broad patient base. Roche holds primary patents and exclusivity rights until at least 2028, with some patent extensions until 2030.
-
Competitive Landscape: Key competitors include Merck's Keytruda (pembrolizumab), Bristol-Myers Squibb's Opdivo (nivolumab), and AstraZeneca's Imfinzi (durvalumab). Keytruda dominates the PD-1/PD-L1 class with approximately 50% market share; Tecentriq holds roughly 10-15%.
-
Market Penetration: Despite late market entry (2016), Tecentriq has captured substantial share, especially in urothelial carcinoma and breast cancer. Its usage remains constrained in markets with established competitors, limiting rapid growth but maintaining steady demand.
-
Pricing Trends: Tecentriq’s current list price in the U.S. approximates $10,000–$13,000 per infusion, typically administered every 2–3 weeks. Price increases have been moderate, around 3-5% annually, aligned with inflation and market adjustments.
Pricing Projections
| Year |
Estimated List Price (per dose) |
Notes |
| 2023 |
$11,500 |
Maintains current pricing, slight inflation adjustment |
| 2024 |
$12,000 |
Moderate increase based on inflation and market factors |
| 2025 |
$12,600 |
Continued inflation adjustment; potential volume growth influences |
| 2026 |
$13,100 |
Inflation plus market-driven price adjustments |
-
Pricing Influencing Factors:
- Increasing competition from biosimilars (expected post-2028).
- Use expansion into additional indications may support price stability.
- Pricing pressures from healthcare systems favoring biosimilars; Roche may adopt slight discounting or value-based pricing.
-
Biosimilar Impact:
Biosimilars for atezolizumab are currently under development, with potential approval post-2028. Their entry could reduce Tecentriq’s price by approximately 20-30% due to market competition.
-
Market Penetration and Volume Effect:
As indications expand, volume growth could offset price declines, supporting stable or increasing revenue with per-dose prices stabilizing.
Revenue and Market Share Projections
| Year |
Estimated Sales (USD billion) |
Market Share |
Key Factors |
| 2023 |
$2.0 |
5% |
Steady uptake; competition constrains share |
| 2024 |
$2.3 |
6% |
Indication expansion; dosing optimization |
| 2025 |
$2.5 |
6-7% |
Growing acceptance; biosimilar threat |
| 2026 |
$2.7 |
7% |
Volume-driven growth; biosimilar competition |
Risks and Opportunities
-
Risks:
- Patent litigation or invalidation resulting in biosimilar entry.
- Clinical trial results not meeting endpoints, limiting indication expansion.
- Pricing pressure reducing margins.
-
Opportunities:
- Additional approvals in unmet cancer subtypes.
- Strategic pricing and biosimilar entry timing.
- Combination therapies enhancing efficacy, expanding use.
Conclusion
Tecentriq remains a high-value immunotherapy with a stable but gradually declining price trajectory aligned with market maturation and biosimilar competition. Revenue growth will depend on indication expansion, pricing strategies, and volume increases, mitigated by increasingly competitive biosimilar landscape.
Key Takeaways
- Tecentriq (NDC 51672-5294) is a major PD-L1 inhibitor with approximate US list prices of $11,500–$13,000 per dose in 2023.
- Price projections show modest increases aligned with inflation; post-2028 biosimilar competition could press prices down by 20–30%.
- Market share growth depends on indication expansion and competitive dynamics, with stability expected until biosimilar entry.
- The global oncology immunotherapy market is expanding rapidly, supported by rising cancer prevalence and new indications.
- Key risks include patent challenges and payer pressure; opportunities include new indications and combination therapies.
FAQs
1. How does Tecentriq’s pricing compare to key competitors?
Tecentriq’s list prices are comparable with Opdivo and Keytruda, which typically range from $10,000–$15,000 per infusion, depending on indication and dosing regimen.
2. What is the expected timeline for biosimilar entry?
Biosimilars for atezolizumab likely will enter the market around 2028, following patent expiry and regulatory approval.
3. How will indication expansion influence Tecentriq’s pricing?
Indication expansion typically supports sustained demand and revenue growth, potentially allowing Roche to maintain or modestly increase prices.
4. Which regions drive Tecentriq’s revenue growth?
The U.S. remains the largest market, followed by Europe and emerging markets. Pricing strategies and reimbursement policies vary regionally.
5. What are the main risks to Tecentriq’s market position?
Patent challenges, biosimilar competition, and shifting payer policies pose significant risks. Clinical trial setbacks could also limit expanded use.
References
[1] Fortune Business Insights. (2022). Oncology Immunotherapy Market Size, Share & Industry Analysis.
